Andrzej Jakubowiak, MD, PhD

Dr Jakubowiak on the Efficacy of KRd Maintenance Therapy Post-ASCT in Multiple Myeloma

November 28th 2025

Andrzej Jakubowiak, MD, PhD, discusses efficacy data with maintenance KRd after ASCT in multiple myeloma.

Dr Jakubowiak on the Design of the Phase 3 ATLAS Trial in Multiple Myeloma

November 21st 2025

Andrzej Jakubowiak, MD, PhD, discusses the design of the phase 3 ATLAS trial in patients with newly diagnosed multiple myeloma after ASCT.

Dr Jakubowiak on How the PERSEUS Study Informed the ATLAS Trial in Multiple Myeloma

November 13th 2025

Andrzej Jakubowiak, MD, PhD, discusses how the data from the PERSEUS Study informed the ATLAS trial in multiple myeloma.

Dr Jakubowiak on the ATLAS Trial of Carfilzomib, Lenalidomide, and Dexamethasone in Myeloma

November 6th 2025

Andrzej Jakubowiak, MD, PhD, discusses the rationale of the phase 3 ATLAS study in patients with multiple myeloma.

Dr. Jakubowiak on Initial Efficacy Data From the ATLAS Trial in Multiple Myeloma

January 30th 2023

Andrzej Jakubowiak, MD, PhD, discusses initial efficacy results from the phase 3 ATLAS trial in multiple myeloma.

Dr. Jakubowiak on Phase I Daratumumab Regimens in Newly Diagnosed Multiple Myeloma

June 12th 2017

Andrzej Jakubowiak, MD, PhD, professor of medicine, director, Myeloma Program, The University of Chicago Medicine, discusses a phase I study of daratumumab (Darzalex) in combination with carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone (KRd) in patients with newly diagnosed multiple myeloma.

Dr. Jakubowiak on Minimal Residual Disease in Multiple Myeloma

September 15th 2016

Andrzej Jakubowiak, MD, PhD, professor of Medicine, director, Myeloma Program, University of Chicago Medicine, discusses minimal residual disease in multiple myeloma.

Dr. Jakubowiak on Finding a Cure for Patients With Multiple Myeloma

July 19th 2016

Andrzej Jakubowiak, MD, PhD, professor of Medicine, director, Myeloma Program, University of Chicago Medicine, discusses the likelihood of finding a cure for patients with multiple myeloma.

Dr. Jakubowiak on Improved Efficacy with ASCT+ KRd in Multiple Myeloma

June 12th 2016

Dr. Jakubowiak Discusses the Future of Multiple Myeloma Treatment

October 17th 2014

Andrzej Jakubowiak, MD, PhD, professor of medicine, director, Myeloma Program, University of Chicago Medicine, discusses the current and future state of multiple myeloma treatmen

Dr. Jakubowiak Discusses the Toxicity Profile of Panobinostat in the PANORAMA Trial

June 17th 2014

Andrzej Jakubowiak, MD, PhD, professor of medicine, director, Myeloma Program, University of Chicago Medicine, discusses the toxicity profile of panobinostat in combination with bortezomib and dexamethasone in relapsed or relapsed/refractory multiple myeloma as seen in the PANORAMA trial.